Aclaris Therapeutics, Inc. (ACRS)

Market Cap	180.22M
Revenue (ttm)	18.72M
Net Income (ttm)	-132.07M
Shares Out	107.92M
EPS (ttm)	-1.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,104,713
Open	1.680
Previous Close	1.700
Day's Range	1.655 - 1.775
52-Week Range	0.952 - 5.170
Beta	0.50
Analysts	Strong Buy
Price Target	11.67 (+598.8%)
Earnings Date	May 6, 2025

About ACRS

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatmen...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 7, 2015
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: ACRS
• Website: https://www.aclaristx.com

Financial Performance

In 2024, Aclaris Therapeutics's revenue was $18.72 million, a decrease of -40.09% compared to the previous year's $31.25 million. Losses were -$132.07 million, 49.3% more than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for ACRS stock is "Strong Buy." The 12-month stock price forecast is $11.67, which is an increase of 598.80% from the latest price.

Price Target

$11.67

(598.80% upside)

Analyst Consensus: Strong Buy